Press Release Feb 24 2022

We are delighted to inform that CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched in March 21, to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other Betacoronaviruses. CEPI will partner with a consortium comprising of the Translational Health Science and Technology Institute (THSTI), an autonomous institute of the Department of Biotechnology, Ministry of Science and Technology, Govt. of India and Panacea Biotec, to develop vaccine candidates that could provide broad protection against SARS-Cov-2 variants and other Betacoronaviruses. CEPI will provide funding of up to $12.5m to support the development of multi-epitope, nanoparticle-based vaccine candidates and advance the manufacturing process. Press Release in this regard is enclosed for your kind reference and record please.

View Attachment